Obagi Medical Sued by Investor Over $360 Million Offer

Obagi Medical Products Inc. (OMPI), which makes prescription-strength skin care systems, was sued by an investor seeking to block a $360 million acquisition by Valeant Pharmaceuticals International Inc. (VRX)

The offer undervalues Obagi, Michael Rubin, the shareholder, said in a filing made public today in Delaware Chancery Court. Rubin seeks to represent all Obagi shareholders in his request for a court order barring the deal.

Obagi announced March 20 that its directors unanimously approved Montreal-based Valeant’s purchase of the company for $19.75 a share in cash. The transaction is expected to close in the second quarter, the companies said in a statement.

Rubin accused Obagi’s board of breach of fiduciary duties, alleging the purchase price was inadequate given the company’s “excellent” prospects for growth, according to the complaint. Deal-protection clauses within the agreement, including a $16.2 million termination fee, preclude other bidders from making a successful competing offer, Rubin said in the complaint.

Mark Taylor, a spokesman for Long Beach, California-based Obagi, didn’t immediately return a phone call seeking comment on the complaint.

The case is Rubin v. Obaji Medical Products Inc., CA8433, Delaware Chancery Court (Wilmington).

To contact the reporter on this story: Sophia Pearson in Philadelphia at spearson3@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.